Browse the search results

NICEdrug.ch is a resource allowing systematic and large-scale computational analysis of drug biochemistry, enzymatic targets, and toxicity in the context of cellular metabolism.

Knocking out the FK506-binding protein in Plasmodium falciparum (PfFKBP35) affects ribosome homeostasis and results in a delayed death-like phenotype that is independent of the mode of action of FK506.

The identification of a conserved α-helical domain in monkeypox virus H3 protein as critical for heparan sulfate binding unveils a novel therapeutic target, validated through AI and molecular dynamics simulations, offering potential for broad-spectrum antiviral development.

The cancer drug vemurafenib has potent off-target effects on JNK signaling that contribute to the development of squamous cell carcinomas in humans and in mice.

Genome-scale metabolic modeling of individual cancer cells and healthy human cells identifies specific and selective metabolic vulnerabilities.

Interactions between viral genomes within the same cells can impact the selection of drug-resistant variants and this has been finessed by hepatitis C virus.

A putative therapeutic target undergoing clinical trials in breast cancer is non-essential and the drug used in those trials blocks cell division through an off-target effect.

Libraries of patient-derived tumor organoids are a reliable and scalable model system that can help identify and optimize targeted therapies in a pre-clinical setting.

Using a cross-species phenotypic drug discovery pipeline, compounds promoting rod photoreceptor survival in zebrafish and mouse models of retinitis pigmentosa were identified, evidence of additive effects of paired compounds and inhibition of PARP-dependent cell death suggest novel therapeutic strategies.

shinyDepMap helps users explore the essentiality, selectivity, and function of the genes across hundreds of cancer cell lines and identify cancer drug targets.